[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332515-105":59,"doc-detail-332515-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-landscape-of-breast-cancer-molecular-and-histologic-subtypes-in-canada","The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada","","Purpose: Characterize the histologic and molecular subtype distribution of breast cancer among Canadian women overall, and assess survival by stage and age at diagnosis. Methods: Invasive breast cancer cases (women aged 15–99, 2012–2017) from the Canadian Cancer Registry were studied using pre-existing mortality linkages, excluding Quebec. Outcomes: Luminal A dominated and stage-specific net survival varied sharply, with the lowest survival in triple negative at advanced stages. Conclusions: Subtype-specific natural histories support prognosis, health system planning, and early detection priorities.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-landscape-of-breast-cancer-molecular-and-histologic-subtypes-in-canada/332515/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-landscape-of-breast-cancer-molecular-and-histologic-subtypes-in-canada/332515.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main purpose?","Question",{"text":113,"@type":114},"To describe the distribution of breast cancer histologic and molecular subtypes in Canada and to evaluate survival by stage and age at diagnosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were cases selected and analyzed?",{"text":118,"@type":114},"Invasive breast cancer cases from the Canadian Cancer Registry for women aged 15–99 between 2012 and 2017 in Canada were examined using pre-existing mortality linkages, excluding Quebec.",{"name":120,"@type":111,"acceptedAnswer":121},"Which breast cancer subtype was most common, and how did survival differ by stage?",{"text":122,"@type":114},"Luminal A was the most common subtype, increasing with age. Net survival was 98% for luminal A across all stages, while triple negative had 74%, with survival decreasing substantially at later stages.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},332515,1790110965,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nThe Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada  \nAnna N. Wilkinson 1, *, Larry F. Ellison 2, Sharon F. McGee 3, Jean-Michel Billette 2 and Jean M. Seely 4  \nCitation: Wilkinson, A.N.; Ellison, L.F.; McGee, S.F.; Billette, J.-M.; Seely, J.M. The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada. Curr. Oncol. 2024, 31, 5544–5556. [https://doi.org/10.3390/](https://doi.org/10.3390/)  \ncurroncol31090411  \nReceived: 9 August 2024  \nRevised: 10 September 2024  \nAccepted: 12 September 2024  \nPublished: 17 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Family Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada  \n2 Centre for Population Health Data at Statistics Canada, Government of Canada, Ottawa, ON K1A 0T6, Canada; larry.ellison@statcan.gc.ca (L.F.E.)  \n3 The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada; [shmcgee@toh.ca](shmcgee@toh.ca)  \n4 Department of Radiology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada; [jeseely@toh.ca](jeseely@toh.ca)  \n* Correspondence: [anwilkinson@toh.ca](anwilkinson@toh.ca)  \nAbstract: Purpose: To characterize the histologic and molecular subtype distribution of, and survival from, breast cancer (BC) among Canadian women overall, and by stage and age at diagnosis. Methods: Invasive BC cases from the Canadian Cancer Registry for women aged 15–99 years between 2012 and 2017 in Canada, excluding Quebec, were examined using pre-existing mortality linkages. Stage at diagnosis, molecular, and histologic subtypes, and 5-year net survival (NS) by age, subtype, and stage were determined. Results: 107,271 women with BC were included. Luminal A was the most common subtype, present in increasing proportions as women aged, up to a maximum of 55% of cases in 70–74 . Ductal and luminal A were most likely to be diagnosed at stage I, while HER2+ had the highest proportion of diagnosis at stage III; triple negative (TN) and unknown had the highest proportion of stage IV. For all stages combined, luminal A had a five-year NS of 98%, while TN was 74% . NS for stage I BC was 99–100% for all subtypes, excepting TN, which was 96% . Survival decreased with advancing stage, most markedly for TN, for which stage III was 47% and stage IV 7% . Survival by equivalent stage and subtype was comparable across age groups but declined in older age categories. Conclusions: The varying natural histories of BC subtypes and histologies can inform prognoses, health system economics, and screening practices. The NS of 96% or greater for stage I, regardless of subtype, highlights the importance of early detection for all subtypes of BC, especially in aggressive subtypes.  \nKeywords: breast cancer; molecular subtype; histology; net survival; outcomes; stage; registries  \n1. Introduction  \nBreast cancer (BC) is not a single biological entity; rather, it is a collection of diseases characterized by discrete histological and molecular subtypes [1] . Ductal and lobular carcinomas are the most common invasive BC histologies. In the absence of definitive gene expression profiling, molecular subtype can be assigned using clinicopathologic elements such as her2/neu (HER2), expression, tumour grade, and the expression of hormone receptor status including estrogen (ER) and progesterone receptors (PR) [2,3] . Recognized molecular subtypes of BC are luminal A (ER+, PR+, HER2−), luminal B (ER+, PR+/ − , HER2+/−), HER2 (ER-, HER2+), and triple negative (TN) (ER-, HER2-) [1,4] . A further division into five subgroups reclassifies some luminal A and B cases into luminal B-like, ","cbCaijCkdrpMXXZu","https://ap.wps.com/l/cbCaijCkdrpMXXZu","pdf",1487000,13,"English","# Abstract\n# Introduction","[{\"question\":\"What was the study’s main purpose?\",\"answer\":\"To describe the distribution of breast cancer histologic and molecular subtypes in Canada and to evaluate survival by stage and age at diagnosis.\"},{\"question\":\"How were cases selected and analyzed?\",\"answer\":\"Invasive breast cancer cases from the Canadian Cancer Registry for women aged 15–99 between 2012 and 2017 in Canada were examined using pre-existing mortality linkages, excluding Quebec.\"},{\"question\":\"Which breast cancer subtype was most common, and how did survival differ by stage?\",\"answer\":\"Luminal A was the most common subtype, increasing with age. Net survival was 98% for luminal A across all stages, while triple negative had 74%, with survival decreasing substantially at later stages.\"}]","The Landscape of Breast Cancer Molecular and Histologic Subtypes in Canada | PDF",1789998562,33]